Drugs / Apotransferrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01797055 | Dec 2010 → Mar 2022 overdue | atransferrinemia | Prothya Biosolutions | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02251041 Comparator | Sep 2014 → Feb 2019 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apotransferrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02251041 ↗ |
| Known as | Human apotransferrin | “Drug: Human apotransferrin” NCT01797055 ↗ |
| Route | Intravenous | “intravenous infusion” NCT01797055 ↗ |